Paris, 19 March 2026 AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENTINCLUDING THE ANNUAL FINANCIAL REPORT Hermès International filed its 2025 Universal Registration Document with the Financial Markets Authority (AMF), on 19 March 2026, in ESEF format. It is available to the public under current regulatory conditions and may be found on finance.hermes.com (under “Investors section” > “Publications” and “Regulated information”) The universal registration document comprises:the annual activity report; the parent company and consolidated financial statements for 2025; the report on sustainability information; the Supervisory Board’s report on the corporate governance; a description of the share buyback programme prepared pursuant to Articles 241-2 and 241-3 of the General Regulation of the Financial Markets Authority (AMF); the...

SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability, as its AI-enabled chronic disease management model continues to scale. Total revenue rose 30.2% year on year to RMB 3.53 billion in 2025, driven by steady growth in its consumer-facing businesses, including comprehensive medical services and online retail pharmacy services, which collectively grew by approximately 30%. The Company also recorded net profit of RMB 12 million, exceeding market expectations and marking a turnaround from a net loss in 2024. Adjusted net profit was up 19%, reaching RMB 20.4 million. This strong performance reflects continued momentum in...

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, March 19, 2026 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the full year ended December 31, 2025, and provided an update on recent corporate developments. “In collaboration with our partner Ultragenyx, we have analysed a significant part of the data from the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta and continue to develop our understanding of the fracture data and the patient reported outcomes (PROs), especially in patients aged 2–18 years...

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to

Revenues for fourth quarter and full year 2025 of $11.8 million and $40.7 million, up 60% and 28% respectively, year-over-year; the strong growth driven by accelerating AI demand Investing strongly in enhancing capabilities, while remaining profitable with FY 2025 net profit of $1.0 million and adjusted EBITDA of $4.4 million TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq: ALAR, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights of Full Year 20252025 revenues of $40.7 million, up 28% year-over-year compared to $31.8 million in 2024. Gross margin of 58.5% compared with 75.1% in 2024, reflecting strategic investments in infrastructure...

DALLAS, March 19, 2026 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced its financial results for the fourth quarter ended December 31, 2025. Key Highlights Since Strive’s Public Listing in September 2025:Accumulated a total of 13,628 bitcoin as of March 17, 2026.5,886 bitcoin from initial PIPE proceeds and 351 exchange. 5,048 bitcoin from acquisition of Semler Scientific, Inc. 2,694 bitcoin from other capital markets activity, including SATA IPO and follow-on, ASST ATM, and SATA ATM.Achieved a Bitcoin Yield of 22.2% in Q4 2025 and 13.8% QTD (as of March 17, 2026) in Q1 2026. Generated a Bitcoin Gain of ₿1,305 BTC in Q4 2025 and ₿1,050 QTD (as of March 17, 2026) in Q1 2026. Generated a Bitcoin $ Gain of $114.3 million in Q4 2025 and $78.2 million QTD (as of March 17, 2026)...

TEJON RANCH, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today announced financial results for the fourth quarter and year-ended December 31, 2025. Fourth-Quarter 2025 Financial HighlightsNet income attributable to common stockholders decreased by $2.9 million to $1.6 million ($0.06/share basic and diluted), compared to $4.5 million ($0.17/share) in fourth quarter of 2024. Revenues and other income, including equity in earnings from unconsolidated joint ventures, increased 8% to $23.3 million, compared to $21.6 million. Farming segment revenues increased 26% to $12.2 million, compared to $9.7 million. Adjusted EBITDA, a non-GAAP measure, increased 9% to $11.4 million, compared to $10.5...

─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Approval for the Treatment of PSC─ ─Multiple Scientific Presentations and Publications Raised Awareness of Nebokitug’s Potential to Become the First Disease-Modifying Treatment for PSC and Its Relevance to Other Fibro-Inflammatory Conditions─ ─Discussions with Strategic Partners Continue to Advance─ TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the full year and fourth quarter ended December...

Completed a strategic growth investment in the fourth quarter into Ability Insurance Company, significantly improving capital ratios and enabling expansion of its business  Mount Logan-managed fund signed a definitive agreement during first quarter 2026 to acquire $100+ million of assets from Yieldstreet Alternative Income Fund, which is expected to increase annual FRE1 by at least $2.8 million2 Entered an agreement during the first quarter 2026 to manage $125 million of additional assets, which is expected to increase FRE by approximately $0.5 million in 2026 and in excess of $1.0 million in 2027  Declared quarterly distribution of $0.03 per common share in the first quarter of 2026, the second shareholder distribution for Mount Logan as a US registrant Mount Logan to host a conference call on Thursday, March 19, 2026, at 12:00 PM Eastern...

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS) InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV) To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this year Active dialog with potential collaborators to expedite the Company’s total pipeline development goals continues InflaRx to host a virtual Capital Markets Day this spring to detail the expected clinical development path for izicopan in HS and to highlight its...